VCYT News & Events

Veracyte announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services', CMS, Molecular Diagnostics Services Program for patients with muscle-invasive bladder cancer, MIBC. The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first molecular residual disease, MRD, offering and the only commercially available truly whole-genome MRD test to come to market, expanding the company's reach into cancer recurrence monitoring.

The company is "raising 2026 total revenue guidance to $582 million to $592 million, or 13% to 14% growth, from prior guidance of $570 to $582 million, or 10% to 13% growth. The company is also raising testing revenue guidance to $570 million to $580 million, or 16% to 18% growth, excluding the contribution from new tests. Additionally, the company is raising guidance for adjusted EBITDA margin to greater than 26%, from approximately 25% prior."